CLINICAL UNIT BASED RESEARCH
In the past decade McLean physicians have been deeply involved in the development and testing of new medications for mental illnesses. Currently twenty principal investigators at McLean are overseeing more than thirty new clinical trials, including agents to treat schizophrenia, bipolar disorder, depression, substance abuse, and Alzheimer's and other neurodegenerative diseases.
- Alcohol and Drug Abuse Treatment Program
Roger D. Weiss, M.D., Director
Conducting clinical research to improve our understanding of alcohol and drug use disorders. - Clinical Psychopharmacology Research Program
Alexander Bodkin, M.D., Director
Studying new methods of delivering antidepressant medication. - Cognitive Neuroscience Laboratory
Dean Salisbury, Ph.D., Director
Studying the relationship between psychiatric symptoms, brain structure, and brain function. - Developmental Biopsychiatry Research Program
Martin H. Teicher, M.D., Ph.D., Director
Exploring the etiology and treatment of psychiatric disorders that arise during development. - Developmental Psychology and Psychopathology Programs
Gil Noam, Dipl. Psych, Ed.D., Director
Community-based prevention/intervention initiatives for Boston area students. - Eating Disorders Education and Prevention
Catherine Steiner-Adair, Ph.D., Director
Full of Ourselves is a dynamic educational program that aims to sustain girls in their health and decrease their vulnerability to the development of body preoccupation and eating disorders. - Geriatric Psychiatry Research Program
James Ellison, M.D., Director - Laboratory for the Study of Adult Development
Mary Zanarini, Ed.D., Director - Nursing Research
Carol Glod, R.N., Ph.D., Director
Studying adolescent depression and its possible treatments. - Personality and Psychosocial Research Program
John G. Gunderson, M.D., Director
Studying the long term course of Borderline Personality Disorder (BPD) and other personality disorders. - Psychopharmacology Research Laboratory
Andrew Stoll, M.D., Director
Focusing on compounds such as Omega-3 fatty acids, which may provide safer treatments for illnesses. - Schizophrenia and Bipolar Disorder Program
Dost Ongur, M.D., Ph.D., Director
Using functional neuroimaging techniques and cognitive neuroscience approaches to understand the neural basis of schizophrenia.